United Therapeutics (NASDAQ:UTHR) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of United Therapeutics (NASDAQ:UTHR) in a report released on Monday morning, Marketbeat reports. The firm issued an overweight rating and a $405.00 price objective on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on the company. JPMorgan Chase & Co. dropped their price target on United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a report on Thursday, May 1st. HC Wainwright reissued a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. Wall Street Zen downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 2nd. Wells Fargo & Company restated an “equal weight” rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Finally, Morgan Stanley increased their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a research note on Thursday, May 1st. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $393.00.

United Therapeutics Price Performance

UTHR opened at $325.48 on Monday. The company has a market capitalization of $14.68 billion, a price-to-earnings ratio of 14.29, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $417.82. The business has a 50 day moving average price of $299.78 and a two-hundred day moving average price of $334.24.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.17 earnings per share. Equities analysts expect that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the sale, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at $11,261,606.58. The trade was a 23.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Raymond Dwek sold 4,000 shares of the business’s stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the sale, the director now directly owns 1,750 shares in the company, valued at $497,962.50. This trade represents a 69.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,500 shares of company stock valued at $16,923,950. 10.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wealthfront Advisers LLC increased its stake in shares of United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Norges Bank acquired a new position in United Therapeutics in the 4th quarter valued at about $151,764,000. FMR LLC grew its stake in United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock valued at $519,170,000 after buying an additional 393,777 shares during the last quarter. Vaughan Nelson Investment Management L.P. acquired a new position in United Therapeutics in the 1st quarter valued at about $101,354,000. Finally, Nuveen LLC acquired a new position in United Therapeutics in the 1st quarter valued at about $83,533,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.